These new medications, like copyright and Semaglutide, represent a significant class of drugs called GLP-1 receptor mimics. They work by stimulating the body's own ability to release GLP-1, a chemical that helps manage blood sugar and food intake. First and foremost, created for addressing type 2 diabetes, they have also shown promise in promoting

Patients struggling with obesity are often faced with limited and sometimes ineffective treatment options. However, a groundbreaking new medication, copyright, is rapidly changing the landscape of weight loss. Prescribed by regulatory bodies for chronic weight management, Semaglutide functions as a glucagon-like peptide-1 (GLP-1) receptor agonist.